Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
This 12-week, double-blind, two-part study in 438 adults with bipolar-associated acute mania began with a 3-week period comparing ziprasidone (80—160 mg/day) and placebo with haloperidol (8—30 mg/day) as active reference. Changes from baseline Mania Rating Scale (MRS) scores for ziprasidone and haloperidol were superior to placebo from day 2 (P = 0.001) to week 3 (P < 0.001); change from baseline at week 3 was greater for haloperidol than ziprasidone (P ≤ 0.001). At week 3, the response rate (≥50% decrease from baseline MRS score) was 36.9, 54.7 and 20.5% for ziprasidone, haloperidol and placebo, respectively (P ≤ 0.05, active treatments versus placebo and ziprasidone versus haloperidol). In the 9-week extension phase, ziprasidone replaced placebo to examine tolerability. Maintenance of improvement was evaluated for ziprasidone (40—160 mg/day) or haloperidol (4—30 mg/day). Responses were maintained through the last visit for 88.1% receiving ziprasidone and 96.3% receiving haloperidol. More patients receiving haloperidol than ziprasidone discontinued treatment during weeks 4—12 (21.1% versus 9.6%) and had significantly higher rates of movement disorders. Mean doses of ziprasidone and haloperidol for the first 3-week and 9-week extension were 116.2 mg/day and 121.4 mg/day and 16.0 mg/day and 16.1 mg/day, respectively. Ziprasidone was shown to be effective monotherapy for acute treatment of bipolar mania. Although haloperidol showed greater efficacy, ziprasidone showed a superior tolerability profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Olanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Smulevich, A. B., Khanna, S., Eerdekens, M., Karcher, K., Kramer, M., & Grossman, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.06.003 · Cited by 192
Atypical antipsychotics in bipolar depression: Neurobiological basis and clinical implications
Brugue, E., & Vieta, E. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.014 · Cited by 54
Self-citation
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., WFSBP Task Force on Treatment Guide, Grunze, H., Vieta, E., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902823202 · Cited by 346
Self-citationCorrell, C. U., Sheridan, E. M., & DelBello, M. P. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00798.x · Cited by 255
Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials
Yildiz, A., Vieta, E., Leucht, S., & Baldessarini, R. J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.192 · Cited by 252
Self-citationCruz, N., Sanchez-Moreno, J., Torres, F., Goikolea, J. M., Valentí, M., & Vieta, E. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990344 · Cited by 121
Self-citation
Metadata
- Authors
- Vieta, E., Ramey, T., Keller, D., English, P., Loebel, A., & Miceli, J.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2008-12-12
- Volume
- 24
- Issue
- 4
- Pages
- 547-558
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2079512442
- Cited by
- 77
- References
- 4
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. https://app.cochat.ai/papers/10.1177/0269881108099418
- The paper
- Vieta, E., Ramey, T., Keller, D., English, P., Loebel, A., & Miceli, J. (2010). Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. Journal of Psychopharmacology. https://doi.org/10.1177/0269881108099418
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.